Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Varian Grows Cancer Portfolio With Endocare & Alicon Acquisitions

Executive Summary

Varian is expanding its cancer care solutions portfolio with two new acquisitions in the interventional oncology space. The medtech giant said it will pay $185m to buy Endocare Systems, based in Austin, Texas; and Alicon, based in Hangzhou, China.

You may also be interested in...



Device/Diagnostics Quarterly Dealmaking Statistics, Q2 2019

Device financing totaled $2.3bn for Q2 2019, with the debt category bringing in the most money. Merger and acquisition deals reached an aggregate $9.1bn (a 25% increase from Q1), thanks mostly to 3M’s  $6.7bn takeover of Acelity and its KCI subsidiaries. Diagnostics/research financing, which totaled $2.4bn, showed a significant rise from the previous quarter, while diagnostics/research tools M&A values, at $233m, exhibited a steep decline.

Boston Scientific Delivers Q2 Sales Growth Across Its Product Lines

Boston Scientific Corp. posted revenue gains across its varied product categories, helped by strong performance in emerging markets.

Varian To Pay $1.3bn For Interventional Oncology Specialist Sirtex

Radiation oncology firm Varian believes Sirtex will allow it to expand into additional areas of cancer treatment.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT125236

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel